CN108367037A - 含有人参皂苷作为有效成分的组合物 - Google Patents
含有人参皂苷作为有效成分的组合物 Download PDFInfo
- Publication number
- CN108367037A CN108367037A CN201680073569.8A CN201680073569A CN108367037A CN 108367037 A CN108367037 A CN 108367037A CN 201680073569 A CN201680073569 A CN 201680073569A CN 108367037 A CN108367037 A CN 108367037A
- Authority
- CN
- China
- Prior art keywords
- steps
- ginsenoside
- ginseng
- saponin
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 37
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 32
- 239000004480 active ingredient Substances 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title claims description 14
- 229930182490 saponin Natural products 0.000 claims abstract description 53
- 150000007949 saponins Chemical class 0.000 claims abstract description 53
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 51
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 50
- 235000008434 ginseng Nutrition 0.000 claims abstract description 45
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 14
- 230000007935 neutral effect Effects 0.000 claims abstract description 14
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000024245 cell differentiation Effects 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 230000004083 survival effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 12
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 108010059820 Polygalacturonase Proteins 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 6
- 240000005373 Panax quinquefolius Species 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 23
- -1 ginseng Natural products 0.000 abstract description 5
- 230000002255 enzymatic effect Effects 0.000 abstract description 4
- 235000002789 Panax ginseng Nutrition 0.000 abstract description 3
- 241000180649 Panax notoginseng Species 0.000 abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 3
- 235000017709 saponins Nutrition 0.000 description 47
- 239000000243 solution Substances 0.000 description 16
- 239000000470 constituent Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000004159 blood analysis Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 6
- 230000002572 peristaltic effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 4
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 206010068052 Mosaicism Diseases 0.000 description 3
- 238000010793 Steam injection (oil industry) Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000003765 sex chromosome Anatomy 0.000 description 3
- 210000004357 third molar Anatomy 0.000 description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical group O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Chemical group CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000010920 waste tyre Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及山参、山养参、培养根、生人参、西洋参、三七或红参等人参皂苷的用途,其目的是延长细胞寿命、促进细胞分化、增加红细胞数量以及减少中性脂肪。具体地,涉及一种人参皂苷的用途,对所述人参皂苷进行提取后,进行热处理并进行酶转化,从而制造包括Compound K在内的活性皂苷Rd、F2、Rg3,含有所述Compound K、Rd、F2、Rg3作为主要成分,含量为90%以上,具有延长细胞寿命、促进细胞分化、增加红细胞数量以及减少中性脂肪的效果。
Description
技术领域
本发明涉及山参、山养参、培养根、生人参、西洋参、三七或红参等人参皂苷(saponins of panax ginseng)的用途,具体地,涉及一种人参皂苷(以下称“CKS”),对所述人参皂苷进行提取后,进行热处理并进行酶转化,从而制造包括CompoundK在内的活性皂苷Rd、F2、Rg3,含有所述Compound K、Rd、F2、Rg3作为主要成分,含量为90%以上,具有延长细胞寿命、促进细胞分化、增加红细胞数量以及减少中性脂肪的效果。
背景技术
人参中所含有的皂苷及非皂苷类物质(人参萜、多糖类、氨基酸衍生物、聚乙炔衍生物、酚类化合物)具有优秀的药理活性,在消除有害氧自由基(free radical)方面具有卓越的效能,并且在抗癌、降血压、降脂质、肝毒性等方面具有优秀的效能。作为人参的主要药理成分被广为人知的人参皂苷分为PPD(原人参二醇,Protopanaxadiol)型及PPT(原人参三醇,Protopanaxatriol)型。PPD型皂苷具有在作为基本结构的PPD结合有多种取代基的结构,人参皂苷(ginsenoside)Rb1、Rb2、Rc、Rd、F2、Rg3、Compound K等是代表性的皂苷。PPT型皂苷的基本结构是PPT,人参皂苷Re、Rf、Rg1、Rh1等具有代表性。
众所周知的是,通常,自然界中存在的很多的糖苷化合物(glycoside compound)与其本身相比,当糖被分解而成为糖苷配基时显示出生理活性增加的趋势,而人参皂苷的情况也一样,与结合有三种以上的糖的人参皂苷Rb1、Rb2、Rd及Re相比,水解一部分的糖而生成的人参皂苷Rg3、Rh1、Rh2、F2、CY以及CK等在生物体内的吸收或生理活性等方面显示出更优秀的效果。大家都知道结合有很多糖的人参皂苷在小肠内被我们身体所吸收的量非常少,对从人的排泄物中提取出的肠内微生物的人参皂苷Rb1的水解能力进行试验的结果显示出,肠内微生物的21%没有分解能力,并且确认了具有分解能力的70%左右的肠内微生物在分解人参皂苷的能力方面具有很大差异。
众所周知的是,通常,含有皂苷成分的人参类产品包含参皂苷,参皂苷由对水的溶解性强的成分构成,尽管非活性状态的所述成分对水的溶解性强,但在肠内很难被吸收,因而几乎没有效果。但是,若所述成分被激活而转化为活性成分,则难以溶于水,但人体内吸收度变高,从而很好地发挥效果。
本发明中,活性皂苷、活性山养参、活性成分等中所使用的所谓“活性”的术语指的是通过本发明加工而成的人参类的皂苷或人参皂苷的特性,粘附在皂苷的核的糖类降低的结果是,相比于普通山参、山养山参或人参,皂苷的总含量高,被人体吸收后得以发挥其效果。换句话说,指的是如下一种皂苷:不是从由结合有三种以上的糖的人参皂苷Rb1、Rb2、Rd及Re组成的组,而是从由水解一部分的糖而生成的人参皂苷Rg3、Rh1、Rh2、F2、CY以及CK组成的组中选择的任意一种或两种以上的人参皂苷,在生物体内的吸收或生理活性等方面显示出更优秀的效果。
如此,所谓的活性成分指的是,粘附在参皂苷的糖脱落的形态的成分,被人体吸收后得以发挥其效果,而该过程主要是利用热进行分解或利用酶进行分解的过程,一部分通过肠内的微生物得到活性化后被吸收。尤其,众所周知的是,作为活性成分的Compound K的制造相当复杂,因而难以制造。
本发明的发明人等制造CKS并进行研究,希望发现针对抗老化的用途。老化是如下一种状态:由于作为生物体的构成成分的细胞和脏器的功能低下以及代谢废物的过度累积,生物体的恒常性降低和细胞的自杀诱导等,生物体难以执行正常功能。此外,可以定义为对疾病和死亡的感受性增加并变衰弱的过程。但是,这样的原因多种多样且复杂,因而很难将其原因归结为一个。
本发明希望通过血液分析对许多老化原因中的内部要因进行确认。随着年龄增长,肝功能下降、肾脏功能下降、记忆力减退,尤其,总脂肪或中性脂肪的过度增加给血管带来问题并成为很多疾病的原因。因此,希望通过血液分析来观察其结果。
因此,购入12个月大的斯普拉-道来氏白鼠(Sprague Dawley Rat,以下称SD鼠),将其饲养至19个月大,从成为20个月大的那天开始,连续37天向其腹腔用药CKS,与未用药的对照组进行比较并观察。Compound K的制造相当复杂,因此,由于昂贵的缺点不易购入并进行试验。本发明的发明人等希望通过长时间的酶转化来制造大量compound K而进行了技术开发,将含有所制造的compoundK的CKS用药于老化了的斯普拉-道来氏白鼠(SpragueDawley Rat,以下称SD鼠)并实施了血液分析。血液分析的结果显示,中性脂肪的减少显著,红细胞有所增加。与活动性大幅降低的对照组相比,药物用药组的活动性活跃,并且希望阐明本发明的发明人等已经申请的专利中有关运动性增加的结果(韩国专利申请号:10-2014-0023244)和追加的理由,通过血液分析可以追加确认CKS的影响。美国食品医药局(FDA)承认了适应症,以便也能够给真性红细胞增多症(polycythemia vera)患者开作为骨髓纤维症的治疗剂的鲁索替尼(ruxolitinib)的处方,与此相似地,也可以将CKS用作红细胞增加效果的用途给患者开CKS的处方。
由于确保老化白鼠需要相对长的时间,具有需要长时间进行饲养的困难,因为是不知道生物体功能什么时候会下降的状况,因此合适的试验设计相当困难。因此,本发明的发明人等每天对白鼠进行观察直至19个月大,将CKS利用于试验中,希望导出通过脂肪分析和血细胞分析得出的结果,并希望通过以老化白鼠为对象的试验导出针对抗老化的好结果。
另外,了解了针对干细胞的分化作用,并且了解了通过细胞培养对细胞的寿命延长的作用。具有干细胞的分化作用是指在短时间内可以制造很多的细胞的意思,尤其,减少分化时间是指能够在短时间内使得细胞的数量增加的意思。
学者们对具有细胞寿命延长作用的物质进行了研究,努力寻找抑制β-乳蛋白酶(β-galactase)的安全物质。但是,寻找这样的物质不容易且利用确保安全性和稳定性的物质很困难。尤其,在经济侧面来说需要考虑价格,而本发明的发明人等长时间研究出的CKS在稳定性、安全性、价格等方面显示出其是最佳的物质。从细胞培养的侧面来说,对培养细胞的β-乳蛋白酶进行抑制指的是细胞的寿命延长的意思,科学家们研究了具有细胞寿命延长作用的物质,本发明的发明人等希望利用具有抑制β-乳蛋白酶效能的CKS导出结果。
发明内容
本发明是为了解决所述现有的问题而提出的,具有以下目的。
本发明的目的在于,通过将粘附于人参皂苷的糖取下来而制造成活性成分,提供一种含有所述人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用的组合物。
此外,本发明的目的在于,提供一种含有人参皂苷作为有效成分、减少干细胞的分化时间、通过抑制细胞内的β-乳蛋白酶对细胞寿命延长有用的组合物。
本发明的目的在于,为了将人参皂苷制造为活性成分,并行热处理和酶处理,另外,使用酒精乙醇进行制造,据此,提供一种克服有害性有机溶剂的残留性问题、含有人参皂苷作为有效成分的组合物。
用于实现如上所述的目的的本发明通过以下解决方法得以实现。
本发明涉及一种含有人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用且具有干细胞的分化作用和细胞的寿命延长作用的组合物,具体地,其特征在于,所述人参皂苷经过以下步骤制成:S1步骤,利用具有多孔隔板的自动温度湿度调节装置将人参放入121℃中,经过10分钟而去除过量的水分,同时使人参在1.1kg/cm2压力下暴露在蒸汽中;S2步骤,连续给经过所述S1步骤的人参注入空气,使温度冷却至90℃以下;S3步骤,再反复进行两次所述S1步骤和所述S2步骤;S4步骤,在所述S3步骤后,使得所述人参在自动温度调节装置内冷却至室温并将所述人参粉碎成大小为1mm以下的粒子;S5步骤,向经过所述S4步骤的人参中添加80%的酒精乙醇,然后提取皂苷并对所述提取的皂苷进行浓缩;S6步骤,在所述S5步骤后,将浓缩的皂苷溶解于乙醇并添加灭菌水,从而制造悬浮液;S7步骤,在所述S6步骤后,将所述悬浮液一滴滴地添加至果胶酶(pectinase)溶液中使发生反应;以及对经过所述S7步骤的反应的溶液进行离心分离然后使其沉淀,使得生成的沉淀物溶解于酒精乙醇后使其重新悬浮于灭菌生理盐水,过滤后对滤液进行浓缩。
此外,本发明是如下一种对红细胞数增加及中性脂肪减少有用、具有干细胞分化作用和细胞的寿命延长作用的药学组合物,其特征在于,所述人参皂苷中,原人参二醇(protopanaxadiol)型皂苷为90%以上,所述原人参二醇型皂苷中,活性原人参二醇为Compound K、Rd、F2、Rg3。
本发明通过前面所述的构成具有以下效果。
本发明的效果在于,通过将粘附于人参皂苷的糖取下来而制造成活性成分,提供一种含有所述人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用的药学组合物,另外,提供一种克服有害性有机溶剂的残留性问题、含有人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用、具有干细胞分化作用和细胞的寿命延长作用的药学组合物。
附图说明
图1是自动温度湿度调节装置的侧面图。
图2是PPT型皂苷和PPD型皂苷的结构。
图3是示出通过酶促反应使得人参类的皂苷中的葡萄糖脱落的过程的图(示出通过酶促反应使得人参皂苷Rb1中的葡萄糖脱落而制造作为活性皂苷的Compound K的过程的图)。
图4是将通过酶促反应使得“热处理皂苷悬浮液”中的葡萄糖脱落的过程图示化的图。
图5是通过HPLC(高效液相色谱法,High Performance Liquid Chromatography)对CKS的活性皂苷进行的分析结果(显示结果为,总皂苷含量中,compound k占52%、Rd占34.4%、F2占2.69%、Rg3占2%)。
图6是通过粒度分析仪对CKS溶液进行分析的结果(分析出平均粒子为1μm以下)。
图7是按照分组从20个月大开始连续37天每天一次向四只SD鼠的腹腔用药CKS,提取血液后分析得出的血液及血细胞的结果(中性脂肪TG通过统计显示出具有显著性的结果。与平均显示450mg/dl的对照组相比,CKS用药试验组以250mg/dl减少至55%水平。此外,总血细胞比容Hct从45%升高至57.8%,红细胞RBC的数值从7X 106个/μl)增加到9.12X106个/μl,大约增加了30%)。
图8是在利用来源于人类牙齿的干细胞的试验中观察间充质干细胞(MSCs,mesenchymal stem cell)的倍增时间(Doubling time)的结果(结果显示,10ng/ml的浓度下PDT(Population stem cell doubling time,干细胞群倍增时间)最少)。
图9是在利用来源于人类牙齿的干细胞的试验中对来源于人类的白细胞癌细胞的PDT进行测量的结果(显示出,10ng/ml的浓度下时间最长,使得白细胞癌细胞的成长速度变慢)。
图10是示出细胞内β-半乳糖苷酶(β-galactosidase)的含量,是利用来源于人类牙齿的干细胞进行评价得出的结果。
具体实施方式
以下,申请人对前面所述的本课题的解决方法进行详细说明。省略被判断为可能不必要地模糊本发明的要旨的公知技术的详细内容。
在本发明中,利用自动温度湿度调节装置对人参进行热处理,所述人参指的是山参、山养参、培养根、生人参、西洋参、三七或人参的根中的任意一种或两种以上。首先,通过图1对自动温度湿度调节装置的结构进行观察,在高温高压的蒸汽前室中处于待机中的蒸汽通过阀门被传送到自动温度湿度调节室,在此通过连续作业制造活性人参并进干燥。如果打开蒸汽注入自动阀,则空气阀自动打开并在自动温度湿度调节室内充满蒸汽,如果除去空气,则空气阀通过自动识别而自动关闭,如果温度和压力达到激活点,则蒸汽注入自动阀关闭并维持10分钟。10分钟后,空气阀自动打开且压力降低。如果温度达到90℃,则再次关闭空气阀而打开蒸汽注入阀,并在自动温度湿度调节室内充满蒸汽,如果除去空气,则空气阀通过自动识别自动关闭,如果温度和压力达到激活点,则蒸汽注入自动阀关闭并维持10分钟。再反复进行一次所述操作,总共经过三次所述操作来对人参进行热处理,使其活性化。
本发明通过热处理制造出活性成分,具体地,在121℃、1.1kg/cm2条件下进行10分钟热处理,一共反复三次(制造加热了的皂苷,以下称作制造“HS”),用粉碎机对HS进行粉碎,将其悬浮于80%药典乙醇(或80%酒精乙醇),提取出皂苷成分。这是因为相比于PPT,在80%的乙醇溶液中更易于提取PPD。对如此提取出的皂苷成分进行蒸发浓缩,然后再将其悬浮于水中,从而用作制造PPD活性的原料。利用管式蠕动泵(Peristaltic pump)将悬浮原料每次以一定量的形式注入酶溶液中,对皂苷的糖侧链进行分解,从而制造出活性成分(制造包括Compound K在内的PPD型皂苷,以下称作制造“CKS”)。在没有每次一定量地将反应原料放入酶中的情况下,收率降低并且因为凝聚的现象不会很好地发生反应。由此,本发明利用管式蠕动泵将反应原料每次以一定量的形式注入酶中,从而制造包括Compound K在内的PPD型的活性成分。对所制造的活性成分进行离心分离并回收后,再次使其悬浮于酒精乙醇中,过滤后对滤液进行浓缩。
以下,根据实施例及附图对本发明进行具体说明。
《实施例1》
利用去除了空气并用蒸汽填充满的自动温度湿度调节装置将包括山养参在内的人参装载于多孔隔板,在121℃条件下经过10分钟使得水分掉落到下面而去除过量的水分,同时在1.1kg/cm2压力下使其暴露于蒸汽中并进行热处理。打开通气阀注入空气的同时,将所述得到热处理的所述人参冷却至90℃以下,然后再反复实施两次相同的操作。
《实施例2》
将实施例1中制造的活性人参细细地粉碎成1mm以下的粒子并进行干燥,在此添加80%酒精乙醇并施加热,然后进行充分提取,提取出活性皂苷。具体地,对制造出的60g活性人参进行粉碎,加入300ml80%酒精乙醇后进行提取,用大约500μm的粒子过滤纸进行过滤,从而去除固体物并对酒精乙醇溶液(以下,称作“热处理皂苷酒精溶液”或“HS酒精溶液”)进行回收。
利用旋转浓缩机(Rotary evaporator)对所述“热处理皂苷酒精溶液”进行浓缩(以下,称作“热处理皂苷浓缩物”或“HS浓缩物”)。将所述“热处理皂苷浓缩物”溶解于少量的酒精乙醇(乙醇)中,加入灭菌蒸馏水后制造悬浮液(以下,称作“热处理皂苷悬浮液”,浓度为0.23w/v%)。为了防止因为污染而产生有害菌,将所述“热处理皂苷悬浮液”保持在50℃以上。
与所述“热处理皂苷悬浮液”单独地,利用温度自动装置将含有果胶酶(商品名Rapidase,DSM food,荷兰)的水溶液(2.4%果胶酶溶液)保持在温度50℃(以下称作“酶溶液”),并向所述酶溶液中一滴滴地连续注入所述“热处理皂苷悬浮液”。所述“热处理皂苷悬浮液”的注入速度为50ml/min。更加详细地进行说明,如图4所示,利用管式蠕动泵(Peristaltic pump)将“热处理皂苷悬浮液”按照每次一定量的形式注入酶溶液(50ml/min),对所制造的成分进行离心分离并回收后,再次使其悬浮于酒精乙醇,进行过滤后对滤液进行浓缩,最终获得浓缩物。从水分含量30%的60g山养参制造出1~1.4g的最终浓缩物,其中,compound k(CK)以52%的比例含量最高,Rd含有34.4%,F2含有2.7%,Rg3含有2%(参照图5及图6)。
[表1]
皂苷 | compound K | F2 | Rd | Rg3 |
含量 | 52% | 2.69% | 34.4% | 2% |
所述最终浓缩物中,CK、Rd、F2、Rg3等PPD型活性成分占91%以上,由于compound k(CK)以52%的比例含量最高,因此,以下称作CKS。
《实施例3》
CKS悬浮剂制造及分析
对所制造的CKS的重量进行称量,添加重10倍的酒精乙醇并溶解后,将它们混入含有0.01%聚山梨醇酯80的灭菌生理盐水中并使它们悬浮化。利用粒度分析仪(Malvernnano ZS-902)对如上所述制造的悬浮液进行分析。分析结果显示,粒子的平均大小为785.5nm,为1μm以下的大小。
《实施例4》
动物用药试验
将在动物室饲养到19个月大为止的雄性SD鼠用于试验,从20个月大开始一共用药37天。将总共10只SD鼠以每5只为一组分成两组,对照组中,将灭菌生理盐水以一天一次每次1ml注入腹腔,试验组作为CKS用药组,将1.25mg/kg浓度的CKS一天一次注入腹腔并利用经无菌处理的CKS悬浮溶液。试验过程中,将产生自然癌的试验组的一只SD鼠从试验中淘汰。第38天时采集血液用于分析。为了进行血液分析,委托专门的血液分析机构(株)绿十字实验室细胞(Green Cross Lab Cell)获取了资料。
分析结果显示,红细胞(RBC)增加了30%,血细胞比容(Hct,hematocrit)从45%增加至57.8%。除此之外,血红蛋白(Hb,haemoglobin)、血小板(Platelet)、总胆固醇(T-cho)、高密度脂蛋白(HDL,high density lipoprotein)、低密度脂蛋白(LDL,Low DensityLipoprotein)没有变化(参照图7)。
《实施例5》
拔取人的智齿提取出干细胞。对干细胞进行细胞培养的同时按照不同浓度添加CKS,计算细胞的数量并以此为基础计算增代时间(或倍增时间)。对照组(Con)平均为46小时,但在10ng/ml的浓度下平均为30小时,减少最多(参照图8)。此外,观察了对癌细胞的抑制能力,利用来源于人类的肺癌细胞A549进行培养后,了解了增代时间,与对照组(Con)的平均增代时间为20小时相比,可以得知使用10ng/ml的CKS的情况增加至平均25小时。虽然在其他浓度中也均显示出增加的趋势,但10ng/ml时显示出最高的增代时间(参照图9)。
《实施例6》
拔取人的智齿提取出干细胞。对干细胞进行细胞培养的同时添加10ng/nl的CKS并实施β-半乳糖苷酶含量分析。可以抑制细胞中β-半乳糖苷酶的表达具有延长细胞的寿命的意思。利用作为来源于人类牙齿的干细胞的间充质干细胞通过酶免疫测量法ELISA(enzyme-linked immuno sorbent assay,酶联免疫吸附测定)对β-半乳糖苷酶的含量进行分析的分析结果为,进行CKS处理时,在分别从三个人分离出的来源于智齿的间充质干细胞(Dental MSCs)中,β-半乳糖苷酶的含量在三个中均减少,第一测试体(Den1)与对照组(con)相比减少16%,第二测试体(Den2)减少10%,第三测试体(Den3)减少12%。β-半乳糖苷酶的含量平均减少12.7%,该结果表明与细胞的寿命延长有关系。
产业利用可能性
本发明在产业上具有以下利用可能性:通过将粘附于人参皂苷的糖取下来而制造成活性成分,提供一种含有所述人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用的药学组合物,另外,提供一种克服有害性有机溶剂的残留性问题、含有人参皂苷作为有效成分、对红细胞数增加及中性脂肪减少有用、具有干细胞分化作用和细胞的寿命延长作用的药学组合物。
Claims (7)
1.一种含有人参皂苷作为有效成分的组合物,其对延长细胞寿命及促进细胞分化有用。
2.根据权利要求1所述的含有人参皂苷作为有效成分的组合物,其特征在于,
通过抑制β-半乳糖苷酶来延长细胞寿命。
3.根据权利要求1所述的含有人参皂苷作为有效成分的组合物,其特征在于,
所述促进细胞分化是促进干细胞分化。
4.一种含有人参皂苷作为有效成分的组合物,其对减少中性脂肪及增加红细胞数量有用。
5.根据权利要求1或4所述的含有人参皂苷作为有效成分的组合物,其特征在于,
所述人参皂苷中,原人参二醇型皂苷为90%以上。
6.根据权利要求5所述的含有人参皂苷作为有效成分的药学组合物,其特征在于,
所述原人参二醇型皂苷中,活性原人参二醇为Compound K、Rd、F2、Rg3。
7.根据权利要求1或4所述的含有人参皂苷作为有效成分的组合物,其特征在于,所述人参皂苷经过以下步骤制成:
S1步骤,利用具有多孔隔板的自动温度湿度调节装置将人参放入121℃中,经过10分钟而去除过量的水分,同时使人参在1.1kg/cm2压力下暴露在蒸汽中;
S2步骤,连续给经过所述S1步骤的人参注入空气,使温度冷却至90℃以下;
S3步骤,再反复进行两次所述S1步骤和所述S2步骤;
S4步骤,在所述S3步骤后,使得所述人参在自动温度调节装置内冷却至室温并将所述人参粉碎成大小为1mm以下的粒子;
S5步骤,向经过所述S4步骤的人参中添加80%酒精乙醇,然后提取皂苷并对所述提取的皂苷进行浓缩;
S6步骤,在所述S5步骤后,将浓缩的皂苷溶解于乙醇并添加灭菌水,从而制造悬浮液;
S7步骤,在所述S6步骤后,将所述悬浮液一滴滴地添加至果胶酶溶液中使发生反应;以及
对经过所述S7步骤的反应的溶液进行离心分离然后使其沉淀,使得生成的沉淀物溶解于酒精乙醇后使其重新悬浮于灭菌生理盐水,过滤后对滤液进行浓缩。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140180180 | 2014-12-15 | ||
KR10-2015-0178493 | 2015-12-14 | ||
KR1020150178493A KR20160072802A (ko) | 2014-12-15 | 2015-12-14 | 인삼류 사포닌을 유효성분으로 포함하는 조성물 |
PCT/KR2016/012231 WO2017104966A1 (ko) | 2014-12-15 | 2016-10-28 | 인삼류 사포닌을 유효성분으로 포함하는 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108367037A true CN108367037A (zh) | 2018-08-03 |
Family
ID=56353418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680073569.8A Pending CN108367037A (zh) | 2014-12-15 | 2016-10-28 | 含有人参皂苷作为有效成分的组合物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10765715B2 (zh) |
JP (1) | JP2018538328A (zh) |
KR (2) | KR20160072802A (zh) |
CN (1) | CN108367037A (zh) |
WO (1) | WO2017104966A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112138033A (zh) * | 2020-10-29 | 2020-12-29 | 光亚生物科技(广州)有限公司 | 一种具有降低尿酸活性的参膏及其制备方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160072802A (ko) * | 2014-12-15 | 2016-06-23 | 경성대학교 산학협력단 | 인삼류 사포닌을 유효성분으로 포함하는 조성물 |
KR20180039539A (ko) * | 2016-10-10 | 2018-04-18 | 경성대학교 산학협력단 | 인삼 사포닌 생산방법 |
US10213306B2 (en) | 2017-03-31 | 2019-02-26 | Neochord, Inc. | Minimally invasive heart valve repair in a beating heart |
WO2019044552A1 (ja) * | 2017-08-29 | 2019-03-07 | Isf合同会社 | ナマコサポニン含有エキス抽出および定量化方法 |
KR102102295B1 (ko) | 2017-10-11 | 2020-04-21 | 경성대학교 산학협력단 | 컴파운드 k 및 데커시놀을 유효성분으로 포함하는 세포의 수명 연장 및 분화 촉진용 조성물 |
AU2019238344B2 (en) | 2018-03-23 | 2021-06-24 | Neochord, Inc. | Device for suture attachment for minimally invasive heart valve repair |
US11173030B2 (en) | 2018-05-09 | 2021-11-16 | Neochord, Inc. | Suture length adjustment for minimally invasive heart valve repair |
US11253360B2 (en) | 2018-05-09 | 2022-02-22 | Neochord, Inc. | Low profile tissue anchor for minimally invasive heart valve repair |
KR102150162B1 (ko) * | 2018-10-15 | 2020-08-31 | 농업회사법인 주식회사 함양산양삼 | 인체 흡수형 진세노사이드가 증진된 활성산양삼 추출액을 포함하는 스틱형 용기용 액상 조성물 및 그 제조방법 |
EP3955855A4 (en) | 2019-04-16 | 2023-01-25 | NeoChord, Inc. | TRANSVERSE HELICAL HEART ANCHOR FOR MINIMALLY INVASIVE HEART VALVE REPAIR |
KR102410301B1 (ko) * | 2019-11-27 | 2022-06-24 | 농업회사법인 주식회사 함양산양삼 | 진세노사이드 컴파운드 케이와 카테킨이 강화된 스틱형 젤리 조성물 및 그 제조방법 |
CN113797237A (zh) * | 2021-10-14 | 2021-12-17 | 天津科技大学 | 一种人参皂苷的提取方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100881634B1 (ko) * | 2008-07-10 | 2009-02-04 | 주식회사 바이럼 | 압출성형, 초음파 및 발효에 의한 우수한 사포닌 함량이증가된 홍삼액과 산삼배양근액 및 장뇌산삼액의 제조방법 |
CN102665725A (zh) * | 2009-12-21 | 2012-09-12 | 狮王株式会社 | 高血脂症改善剂、贫血改善组合物、尿酸值降低组合物以及饮料食品 |
KR20150078868A (ko) * | 2013-12-31 | 2015-07-08 | (주)에이씨티 | 진세노사이드 Rd, Rb2와 죽여추출물을 유효성분으로 함유하는 주름개선 및 보습용 화장료 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4885611B2 (ja) * | 2006-05-15 | 2012-02-29 | 株式会社ニチレイフーズ | γ−アミノ酪酸含有人参発酵物及びその製造方法 |
WO2010134650A1 (en) * | 2009-05-19 | 2010-11-25 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
KR20110007473A (ko) * | 2009-07-16 | 2011-01-24 | 씨제이제일제당 (주) | 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물 |
KR100992800B1 (ko) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법 |
KR20120089974A (ko) | 2011-01-11 | 2012-08-16 | 한국산업기술대학교산학협력단 | 고온 고압 추출법을 이용한 프로토파낙사디올계 사포닌의 분획추출방법 및 그 방법에 의하여 추출된 프로토파낙사디올계 사포닌 |
KR20150068865A (ko) * | 2013-12-12 | 2015-06-22 | 한국기초과학지원연구원 | 진세노사이드 Rg3를 유효성분으로 포함하는 노화세포 회춘용 조성물 |
KR101557410B1 (ko) | 2014-02-27 | 2015-10-26 | 경성대학교 산학협력단 | 운동수행능력 증강용 조성물 |
KR20160072802A (ko) | 2014-12-15 | 2016-06-23 | 경성대학교 산학협력단 | 인삼류 사포닌을 유효성분으로 포함하는 조성물 |
-
2015
- 2015-12-14 KR KR1020150178493A patent/KR20160072802A/ko not_active Application Discontinuation
-
2016
- 2016-10-28 WO PCT/KR2016/012231 patent/WO2017104966A1/ko active Application Filing
- 2016-10-28 US US16/062,101 patent/US10765715B2/en active Active
- 2016-10-28 CN CN201680073569.8A patent/CN108367037A/zh active Pending
- 2016-10-28 JP JP2018532276A patent/JP2018538328A/ja active Pending
-
2017
- 2017-09-28 KR KR1020170126442A patent/KR101889866B1/ko active IP Right Grant
-
2020
- 2020-04-22 US US16/854,905 patent/US11007240B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100881634B1 (ko) * | 2008-07-10 | 2009-02-04 | 주식회사 바이럼 | 압출성형, 초음파 및 발효에 의한 우수한 사포닌 함량이증가된 홍삼액과 산삼배양근액 및 장뇌산삼액의 제조방법 |
CN102665725A (zh) * | 2009-12-21 | 2012-09-12 | 狮王株式会社 | 高血脂症改善剂、贫血改善组合物、尿酸值降低组合物以及饮料食品 |
KR20150078868A (ko) * | 2013-12-31 | 2015-07-08 | (주)에이씨티 | 진세노사이드 Rd, Rb2와 죽여추출물을 유효성분으로 함유하는 주름개선 및 보습용 화장료 조성물 |
Non-Patent Citations (3)
Title |
---|
GUO-XIANG LI: "The protective effects of ginsenosides on human erythrocytes", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
HYUN-JUNG LEE: "The effect of ginsenosides on hepatogenic differentiation using placenta-derived stem cells as an in vitro screening system",Hyun-Jung Lee", 《MOLECULAR & CELLULAR TOXICOLOGY》 * |
JIE LI: "Ginsenoside-Rd, a purified component from panax notoginseng saponins, prevents", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112138033A (zh) * | 2020-10-29 | 2020-12-29 | 光亚生物科技(广州)有限公司 | 一种具有降低尿酸活性的参膏及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2017104966A1 (ko) | 2017-06-22 |
US10765715B2 (en) | 2020-09-08 |
US20200246407A1 (en) | 2020-08-06 |
US20180369309A1 (en) | 2018-12-27 |
KR20170119656A (ko) | 2017-10-27 |
US11007240B2 (en) | 2021-05-18 |
KR20160072802A (ko) | 2016-06-23 |
KR101889866B1 (ko) | 2018-09-28 |
JP2018538328A (ja) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108367037A (zh) | 含有人参皂苷作为有效成分的组合物 | |
Gowd et al. | Anthocyanins as promising molecules and dietary bioactive components against diabetes–A review of recent advances | |
Wang et al. | Comparison of antidiabetic effects of saponins and polysaccharides from Momordica charantia L. in STZ-induced type 2 diabetic mice | |
Bendjeddou et al. | Immunostimulating activity of the hot water-soluble polysaccharide extracts of Anacyclus pyrethrum, Alpinia galanga and Citrullus colocynthis | |
TWI454269B (zh) | 由文冠果(xanthoceras sorbifolia)單離之化合物、其製備方法以及其用途 | |
Nair et al. | Evaluation of in vitro antidiabetic activity of selected plant extracts | |
CN105079046B (zh) | 一种全灵芝抗肿瘤软胶囊及其制备方法 | |
KR101972691B1 (ko) | 상승적인 글리코칼릭스 치료 조성물 및 방법 | |
CN102961424A (zh) | 一种三七多糖提取物及其制备方法与制剂及应用 | |
CN108047343B (zh) | 伊贝母总多糖的制备方法及其应用 | |
CN110790848A (zh) | 沙棘总多糖的制备方法及其应用 | |
CN101879274B (zh) | 包含红参皂苷提取物和麦冬皂苷提取物的药物组合物、其制备方法和用途 | |
Li et al. | Genotoxicity and subchronic toxicological study of a novel ginsenoside derivative 25-OCH3-PPD in beagle dogs | |
CN107412440A (zh) | 一种复方红衣补血口服液及其质量检测方法 | |
Rao et al. | Hypoglycemic and antidiabetic potential of chitosan aqueous extract of Elaeocarpus ganitrus | |
Sarkar et al. | Evaluation of in vitro anti diabetic activity of two mangrove plant extracts: Heritiera fomes and Sonneratia apetala | |
CN105851764B (zh) | 一种青钱柳叶固体饮料及其制备方法和应用 | |
KR20060117401A (ko) | 상황버섯 및 가공인삼을 이용하여 다량의 Rg3와 Rg5를 함유하는 기능성 조성물의 제조방법 및 이를 이용한 기능성 다류의 제조방법 | |
WO2020000828A1 (zh) | 一种具有显著降血脂活性的龙须菜多糖及其制备方法与应用 | |
Sasongko et al. | Antidiabetic and Antioxidant Effect Combination Vasconcellea pubescens A. DC. and Momordica charantia L. Extract in Alloxan-Induced Diabetic Rats | |
CN114366826A (zh) | 一种落叶松阿拉伯半乳聚糖组合物的制备方法及其灭菌处理装置 | |
KR101796368B1 (ko) | 돼지감자 함유 삼투압 효소 발효물 천연 리포좀, 그 제조방법, 및 이를 포함하는 화장료, 식품 또는 약학 조성물 | |
CN110812415B (zh) | 一种改善睡眠的益心宁神组合物的制备方法 | |
CN109568406A (zh) | 一种含蜂胶提取物的治疗老年痴呆的药物组合物及其制备方法和用途 | |
CN107308215A (zh) | 一种植物源性降糖降脂药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180803 |
|
WD01 | Invention patent application deemed withdrawn after publication |